Abstract
Small interfering RNA (siRNA)-based therapy has been subject of intense research since the discovery of RNA interference (RNAi), providing a tool to potentially silence any chosen gene. Nevertheless, efficient delivery still presents a major hurdle to translating this promising technology into medical practice. Here, we describe a straightforward method to prepare and characterize an effective delivery system consisting of low-molecular-weight polyethylenimine (PEI) and transferrin (Tf). Tf-PEI polyplexes are not only able to successfully transport and protect the sensitive nucleic acid payload from degradation but also to selectively deliver the siRNA to transferrin receptor (TfR)-overexpressing cells, playing key roles in the pathology of numerous cancer types as well as inflammatory diseases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mocellin S, Provenzano M (2004) RNA interference: learning gene knock-down from cell physiology. J Transl Med 2(1):39. https://doi.org/10.1186/1479-5876-2-39
Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G (2015) Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108–119. https://doi.org/10.1016/j.addr.2015.01.007
Hoy SM (2018) Patisiran: first global approval. Drugs 78(15):1625–1631. https://doi.org/10.1007/s40265-018-0983-6
Kandil R, Merkel OM (2016) Therapeutic delivery of RNA effectors: diseases affecting the respiratory system. Pharmazie 71(1):21–26
Merkel OM, Rubinstein I, Kissel T (2014) siRNA delivery to the lung: what’s new? Adv Drug Deliv Rev 75C:112–128. https://doi.org/10.1016/j.addr.2014.05.018
Maeda H (2012) Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting. Proc Jpn Acad Ser B Phys Biol Sci 88(3):53–71
Nakamura Y, Mochida A, Choyke PL, Kobayashi H (2016) Nanodrug delivery: is the enhanced permeability and retention effect sufficient for curing cancer? Bioconjug Chem 27(10):2225–2238. https://doi.org/10.1021/acs.bioconjchem.6b00437
Matsumura Y, Maeda H (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 46(12 Pt 1):6387–6392
Nehoff H, Parayath NN, Domanovitch L, Taurin S, Greish K (2014) Nanomedicine for drug targeting: strategies beyond the enhanced permeability and retention effect. Int J Nanomedicine 9:2539–2555. https://doi.org/10.2147/IJN.S47129
Sofou S, Sgouros G (2008) Antibody-targeted liposomes in cancer therapy and imaging. Expert Opin Drug Deliv 5(2):189–204. https://doi.org/10.1517/17425247.5.2.189
Eloy JO, Petrilli R, Raspantini GL, Lee RJ (2018) Targeted liposomes for siRNA delivery to cancer. Curr Pharm Des 24(23):2664–2672. https://doi.org/10.2174/1381612824666180807121935
Daniels TR, Bernabeu E, Rodriguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet ML (2012) The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 1820(3):291–317. https://doi.org/10.1016/j.bbagen.2011.07.016
Shen Y, Li X, Dong D, Zhang B, Xue Y, Shang P (2018) Transferrin receptor 1 in cancer: a new sight for cancer therapy. Am J Cancer Res 8(6):916–931
Lakkadwala S, Singh J (2018) Co-delivery of doxorubicin and erlotinib through liposomal nanoparticles for glioblastoma tumor regression using an in vitro brain tumor model. Colloids Surf B Biointerfaces 173:27–35. https://doi.org/10.1016/j.colsurfb.2018.09.047
Xie Y, Kim NH, Nadithe V, Schalk D, Thakur A, Kilic A, Lum LG, Bassett DJ, Merkel OM (2016) Targeted delivery of siRNA to activated T cells via transferrin-polyethylenimine (Tf-PEI) as a potential therapy of asthma. J Control Release 229:120–129. https://doi.org/10.1016/j.jconrel.2016.03.029
Fra AM, Williamson E, Simons K, Parton RG (1994) Detergent-insoluble glycolipid microdomains in lymphocytes in the absence of caveolae. J Biol Chem 269(49):30745–30748
Movassaghian S, Xie Y, Hildebrandt C, Rosati R, Li Y, Kim NH, Conti DS, da Rocha SR, Yang ZQ, Merkel OM (2016) Post-transcriptional regulation of the GASC1 oncogene with active tumor-targeted siRNA-nanoparticles. Mol Pharm 13(8):2605–2621. https://doi.org/10.1021/acs.molpharmaceut.5b00948
Acknowledgments
This work was supported by the ERC Starting Grant ERC-2014-StG—637830 “Novel Asthma Therapy.”
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Kandil, R., Xie, Y., Mehta, A., Merkel, O. (2020). A Method for Targeted Nonviral siRNA Delivery in Cancer and Inflammatory Diseases. In: Jain, K. (eds) Drug Delivery Systems. Methods in Molecular Biology, vol 2059. Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9798-5_7
Download citation
DOI: https://doi.org/10.1007/978-1-4939-9798-5_7
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-4939-9797-8
Online ISBN: 978-1-4939-9798-5
eBook Packages: Springer Protocols